Article
Amgen Falls 10% as Novartis Trial Failure Clouds a Cholesterol Drug Class; NVS Stock Drops 14%
Bearish
-55.0
−100 Bearish
0
+100 Bullish
Novartis just handed the entire Lp(a) drug class a failing grade, and Amgen is taking the worst of the punishment despite releasing promising trial results of its own on the very same morning.
Actions
Pulse AI
Pulse analysis not available yet. Click "Get Pulse" above.
Generated by Pulse AI, Glideslope's proprietary engine for interpreting market sentiment and economic signals. For informational purposes only — not financial advice.
Article Info
Source
finance.yahoo.com
Published
Sep 8, 2026 · 1:08 pm
Article ID
RD5MGLD
Original URL
Open source
Sentiment Signal
Bearish
-55.0
−100Neutral+100
More Like This